ASH 2024: Updates in the Treatment of CLL - Episode 1
Expert Insights in Selecting Frontline Therapies in TN CLL: Fixed-Duration Venetoclax vs Continuous BTKi
Matthew S. Davids, MD, MMSc; Alvaro Alencar, MD; Marc S. Hoffmann, MD; Brad S. Kahl, MD; and Nicole Lamanna, MD, engage in a comprehensive discussion of frontline CLL treatment strategies, examining factors influencing the choice between fixed-duration venetoclax-based therapy and continuous BTK inhibitors, analyzing long-term SEQUOIA trial data, evaluating real-world outcomes and adverse events with covalent BTK inhibitors, and assessing emerging combination approaches including zanubrutinib plus venetoclax.
Video content above is prompted by the following:
How do you typically select between a fixed-duration venetoclax-based therapy vs continuous BTKi therapy in the frontline setting? How does the presence of high-risk features (del17p, TP53 mutations) influence your treatment decision?
Related Content:
